

60<sup>TH</sup> ERA  
CONGRESS  
MILAN & VIRTUAL  
JUNE 15-18, 2023

AMAZING NEPHROLOGY













INDUSTRY  
SYMPOSIA  
BOOKLET



10:00   11:00	ROOM	SESSION	SESSION TITLE
	Space 1&2	ISS 1.1	KDIGO 2023 CKD Guideline: A Brave New World on the Evaluation, Prognostication, and Management of Kidney Disease
	Space 3&4	ISS 1.2	Genetic Screening in adult patients with end-stage kidney disease (ESKD)
	Brown 3	ISS 1.3	C3G and IC-MPGN: From unmet needs to a collaborative approach towards improving outcomes
	Brown 1&2	ISS 1.4	IgA Nephropathy: Where we are now and where we are going.
	Amber 1&2	ISS 1.5	The window of opportunity in lupus nephritis: when to act to improve kidney outcomes?
	Amber 3&4	ISS 1.6	From first evidence to future therapy: Learnings from 2 decades of Fabry experience
	Amber 5	ISS 1.7	Potassium control across the spectrum of CKD – optimising RAASi therapy and improving patient outcomes

13:30   14:30	ROOM	SESSION	SESSION TITLE
	Space 1&2	ISS 1.8	Beyond the kidney: new perspectives in inherited rare diseases
	Space 3&4	ISS 1.9	GLP-1 RAs: towards an unmet need of people with T2D and CKD
	Brown 3	ISS 1.10	Inspired to move mountains: emerging therapies in lupus nephritis
	Brown 1&2	ISS 1.11	ANCA-associated vasculitis, the kidney and beyond
	Amber 1&2	ISS 1.12	Anemia of CKD: time to take action
	Amber 3&4	ISS 1.13	Explore the latest hot topic within IV Iron in CKD and Heart Failure
	Amber 5	ISS 1.14	What's new in the management of atypical haemolytic uraemic syndrome?
18:30   19:30	ROOM	SESSION	SESSION TITLE
	Amber 1&2	ISS 1.15	Adsorption in Chronic and Acute Clinical Settings
	Amber 3&4	ISS 1.16	Lupus Nephritis: current challenges and novel treatment strategies.

10:00   11:00	ROOM	SESSION	SESSION TITLE
 NOVARTIS   Reimagining Medicine	Space 1&2	ISS 2.1	Challenges and opportunities in IgA Nephropathy: Targeting the alternative complement pathway 
	Space 3&4	ISS 2.2	Strengthening expertise in the treatment of chronic kidney disease 
	Brown 3	ISS 2.3	Continuing lifesaving therapy in the cardiorenal patient: Practical guidance for managing hyperkalemia 
	Brown 1&2	ISS 2.4	Through different lenses: understanding the complexity of C3G and IC-MPGN
	Amber 1&2	ISS 2.5	Filling the gap by targeting the gut - First disease modifying treatment approved for IgAN 
	Amber 3&4	ISS 2.6	Therapeutic Apheresis: Future Challenges
	Amber 5	ISS 2.7	Patient-centered care in dialysis: let's tackle CKD-associated Pruritus 

13:30   14:30	ROOM	SESSION	SESSION TITLE
	Space 1&2	ISS 2.8	This live activity is developed by Medtelligence and supported by an independent educational grant from CSL Vifor. 
	Amber 1&2	ISS 2.9	Reshaping kidney care – Establishing the full potential of SGLT2 inhibitors as standard-of-care 
	Brown 3	ISS 2.10	Immuno-nephrology: the dialysis membrane as a therapeutic strategy
	Brown 1&2	ISS 2.11	Hemocompatibility of dialyzers – How novel membranes may improve hemodialysis treatment
	Amber 1&2	ISS 2.12	Non-Steroidal MRAs: a new pillar of treatment for cardiorenal protection in CKD and T2D 
	Amber 3&4	ISS 2.13	Complex pathophysiology and management in anaemia of CKD: is roxadustat the answer? 
	Amber 5	ISS 2.14	Ensuring a treatment continuum for CKD-MBD 





**KDIGO 2023 CKD GUIDELINE:  
A Brave New World on the Evaluation,  
Prognostication, and Management of Kidney Disease**

**FRIDAY, JUNE 16 | 10AM-11AM  
SPACE 1&2 | MICO CONVENTION CENTRE  
ERA CONGRESS 2023 | MILAN, ITALY**

**Chairperson**

**ADEERA LEVIN | CANADA**

**Vision for the Guideline: Why now?**

**PAUL STEVENS | UNITED KINGDOM**

**Evaluation of CKD: What's changed?**

**RUMEYZA KAZANCIUGLU | TURKEY**

**Delaying CKD Progression and Complications: What's new?**

**MAGDALENA MADERO | MEXICO**

Supported by







ERA 2023 CONGRESS – MILAN

# GENETIC SCREENING IN ADULT PATIENTS WITH END-STAGE KIDNEY DISEASE (ESKD)



**Prof. Pietro Manuel Ferraro**  
Catholic University of the Sacred Heart  
of Rome, Italy



**Prof. Nine Knoers**  
University Medical Centre Groningen,  
The Netherlands



**Prof. Carsten Bergmann**  
Medizinische Genetik  
Mainz, Germany

Friday, 16 June 2023, 10:00–11:00, MiCo, Rooms 3 & 4

10:00–10:05	Welcome and introductions	Prof. Pietro Manuel Ferraro
10:05–10:20	Clinical utility of genetic testing in adult patients with CKD and ESKD	Prof. Nine Knoers
10:20–10:35	Overcoming the challenges of and barriers to genetic screening in routine clinical practice	Prof. Carsten Bergmann
10:35–10:50	How to successfully implement a screening programme for a rare genetic condition	Prof. Pietro Manuel Ferraro
10:50–11:00	Panel discussion and summary	All

Chronic Kidney Disease (CKD). The European Renal Association (ERA) assumes no responsibility for the information published in this document. For healthcare professionals only. You will need to be registered for the congress to attend. Registration conditions differ internationally; please refer to your local prescribing information for further information. To report adverse events, please refer to your local reporting guidelines. © 2023 Alnylam Netherlands B.V. All rights reserved. April 2023 PH1-CEMEA-00113. This is a non-promotional meeting, funded and organised by Alnylam.



Visit [alnylamconnect.eu](https://alnylamconnect.eu) to sign up to receive further information about PH1 from Alnylam.



Novartis-sponsored satellite symposium  
on C3 glomerulopathy

ERA 2023

C3G and IC-MPGN: From unmet needs to a collaborative  
approach towards improving outcomes

Welcome from the Chair

It is our great pleasure to welcome you to the Novartis-sponsored symposium at this year's 60<sup>th</sup> European Renal Association (ERA) Congress 2023.

The symposium entitled **C3G and IC-MPGN: From unmet needs to a collaborative approach towards improving outcomes** will examine the current state of evidence and clinical management in C3G and IC-MPGN and discuss about the CompCure Association and the European Registry for C3G and IC-MPGN.

Our expert faculty will explore these topics via clinical case presentations and engaging panel discussions, and we warmly encourage your active participation during the Q and A session. We hope you enjoy what will be an interesting and informative session.

**Fadi Fakhouri**

*(Chair for C3G and IC-MPGN symposium)*

*Centre Hospitalier Universitaire Vaudois and Université de Lausanne, Lausanne, Switzerland*

C3G and IC-MPGN: From unmet needs to a collaborative approach  
towards improving outcomes

16 June 2023 | 10:00–11:00 (CET) | ERA Congress 2023  
MiCo – Milano Convention Centre, Milan, Italy

Room number: Brown 3, Level 2

- 10:00 Welcome and introduction**  
Chair: Fadi Fakhouri
- 10:05 Current state of evidence in C3G and IC-MPGN and impact of uncertainties on clinical management**  
Fadi Fakhouri
- 10:25 The CompCure Association - committed to improving outcomes in C3G and IC-MPGN**  
Marianne Silkjaer-Nielsen
- 10:30 A comprehensive European Registry for C3G and IC-MPGN**  
Marianne Silkjaer-Nielsen & Franz Schaefer
- 10:45 Audience Q and A**  
All faculty (moderated by Chair)
- 10:58 Closing remarks**  
Chair: Fadi Fakhouri

Faculty



**Fadi Fakhouri (Chair)**  
Centre Hospitalier Universitaire Vaudois and  
Université de Lausanne, Lausanne, Switzerland



**Marianne Silkjaer-Nielsen**  
CompCure, Aarhus, Denmark




**Franz Schaefer**  
University Children's Hospital  
Heidelberg, Heidelberg, Germany



60TH ANNUAL EUROPEAN RENAL ASSOCIATION CONGRESS

# Chinook Therapeutics: IgA Nephropathy: where we are now and where we are going.

PRESENTED BY:



**Dana Rizk, MD**

Professor of Medicine, Nephrology Division  
The Anupam Agarwal Endowed Scholar in Nephrology  
Director of Clinical Trials Research, Nephrology Division  
Medical Director of Clinical Trials Administrative Office  
University of Alabama at Birmingham



**Rosanna Coppo,  
MD, FERA**

Fondazione Ricerca Molinette  
Past Director of Nephrology, Dialysis and  
Transplantation, Regina Margherita Children's  
Hospital, Turin, Italy  
International IgAN Network Research Group

SUPPORTED BY



The Exhibitor Spotlight is not a  
Continuing Education (CE) activity

Friday


June 16, 2023

10:00 – 11:00 am

CEST

MiCo – Milano  
Convention Centre

Brown Hall 1&2







For Healthcare Professionals only

# The window of opportunity in lupus nephritis: when to act to improve kidney outcomes?

16<sup>th</sup> June, 10:00–11:00 CEST (UTC +2)

Room Amber 1 & 2, MiCo Convention Centre, Milan, Italy



**Professor Liz Lightstone, UK,**  
will chair expert discussions of clinical case studies centred  
around lupus nephritis management




Forward thinking in the management of lupus nephritis  
**Dr Lucio Manenti, Italy**



Can we meet the challenge to improve kidney outcomes  
in lupus nephritis?  
**Professor Onno Teng, the Netherlands**

The event was duly communicated to the competent AIFA office, within the terms and in the manner established by art. 124, co. 1 of Legislative Decree 219/06 and subsequent implementing provisions, and complies with the requirements established by the current Farmindustria Code of Conduct.

An industry symposium sponsored and organised by GSK. GSK products will be discussed. Prescribing Information for all GSK products discussed will be available at the event and the GSK booth.



PM-GBL-BEL-ADVT-230015  
Date of preparation: March 2023

# FROM FIRST EVIDENCE TO FUTURE THERAPY: Learnings from 2 decades of Fabry experience

— AGENDA —

Welcome and introduction	<b>Antonio Pisani</b> <i>Department of Nephrology, University Federico II, Italy</i>
More than 20 years of the patient-centered Fabry Registry: Real-world scientific evidence advancing Fabry disease expertise and better informing the Fabry community	<b>Alberto Ortiz</b> <i>Fundación Jiménez Díaz, Spain</i>
Cleared podocytes and normal kidney function in classical Fabry males 15 years after start of enzyme replacement therapy at young age	<b>Camilla Tøndel</b> <i>University of Bergen and Haukeland University Hospital, Norway</i>
Future oral therapies focusing on glucosylceramide synthase inhibition: Evidence from clinical programs	<b>Patrick Deegan</b> <i>Cambridge University Hospitals NHS Foundation Trust, UK</i>
Q&A and panel discussion	<b>All</b>

**Friday 16th June 2023**  
**10:00–11:00 (CET)**

**Room Amber 3&4**



**Prof Antonio Pisani**  
 Department of Nephrology,  
 University Federico II, Italy



**Prof Alberto Ortiz**  
 Health Research Institute of the  
 Jiménez Díaz Foundation, Spain



**Prof Camilla Tøndel**  
 University of Bergen and Haukeland  
 University Hospital, Norway



**Dr Patrick Deegan**  
 Cambridge University Hospitals  
 NHS Foundation Trust, UK







EBAC ACCREDITED EDUCATIONAL PROGRAMME  
DURING THE 60<sup>th</sup> ERA CONGRESS

# POTASSIUM CONTROL ACROSS THE SPECTRUM OF CKD – OPTIMISING RAASI THERAPY AND IMPROVING PATIENT OUTCOMES



FRIDAY, JUNE 16, 2023  
10:00–11:00 CEST  
AMBER 5 ROOM



Please scan this QR code  
to complete the EBAC evaluation form

**Chair: Francesca Mallamaci, Reggio Calabria, Italy**

10:00–10:03

**Welcome and introduction**

*Francesca Mallamaci, Reggio Calabria, Italy*

10:03–10:18

**Hyperkalaemia – still an issue in the management of CKD?**

*Maria C. Haller, Linz, Austria*

10:18–10:33

**Potassium control across the spectrum of CKD**

**– practical guidance and novel therapeutic options**

*Patrick Rossignol, Monaco, Monaco*

10:33–10:48

**Optimising RAAS inhibition in patients with CKD and comorbidities**

**– current guidelines and lessons from recent trials**

*Charles J. Ferro, Birmingham, UK*

10:48–10:58

**Interactive panel discussion**

*All faculty*

10:58–11:00

**Concluding comments**

*Francesca Mallamaci, Reggio Calabria, Italy*

EDUCATIONAL OBJECTIVES:

- Describe prognostic implications and dynamics of serum potassium in patients with chronic kidney disease (CKD) requiring or not requiring dialysis
- Recognise the importance of hyperkalaemia as a threat to patient safety and as a barrier to optimal renin–angiotensin–aldosterone system inhibitor (RAASi) therapy in patients with CKD
- Highlight the need for close monitoring of serum potassium in patients with CKD
- Evaluate the role of novel potassium binders in optimising the use of RAASi therapy in patients with CKD and other risk factors for hyperkalaemia
- Discuss the cardiorenal benefits of RAASi therapy and current guidelines for their use in patients with CKD and comorbidities such as heart failure, resistant hypertension and type 2 diabetes



Join us on



Friday June 16, 2023

Time: 1:30 – 2:30 CEST

Space 1&2

At 60th ERA CONGRESS | MILAN and VIRTUAL

## CHIESI INDUSTRY SYMPOSIUM

# BEYOND THE KIDNEY: new perspectives in inherited rare diseases

The symposium will be a combined one between Nephropathic Cystinosis (NC) and Fabry Disease (FD), providing a patient centric overview of the current unmet needs through clinical cases and new data.

## AGENDA

Welcome and Introduction – **C. Wanner**

The importance of patients' perspective for the assessment of symptoms: the unmet needs in FD from a patients' perspective. Results of the patients'survey – **R. Torra**

Adult patients' management in NC: clinical case reports – **A. Servais**

How to update the optimal monitoring in FD considering the new data – **A. Pisanl**

Closing & remarks – **C. Wanner**

### Chairman and Moderator:



**Christoph Wanner** (Wurzburg, Germany)

### Speakers:



**Roser Torra** (Barcelona, Spain)



**Aude Servais** (Paris, France)



**Antonio Pisanl** (Naples, Italy)



ERA 2023 Novo Nordisk symposium

# GLP-1 RAs: towards an unmet need of people with T2D and CKD

Friday, June 16<sup>th</sup> 2023, 13:30-14:30 (CEST)  
MiCo – Milano Convention Centre, Milan, Italy

Dear colleagues,

On behalf of Novo Nordisk, I am delighted to invite you to the Novo Nordisk industry symposium at ERA 2023 entitled “GLP-1 RAs: towards an unmet need of people with T2D and CKD”. The ERA Annual Symposium will be held face-to-face in Milan on June 16<sup>th</sup> at 13:30-14:30 (CEST) and broadcasted online.

Chronic kidney disease (CKD) is a common complication of Type 2 Diabetes (T2D), presence of which also significantly amplifies the risk of cardiovascular diseases (CVD). The current medical guidelines emphasize on a holistic approach, to consider CKD and CVD status from the beginning while treating people with T2D.

In this symposium, with our world-renowned faculty, we aim to highlight unmet medical needs for management of CKD in people with T2D. We will be discussing about the current landscape of the treatment options available for the people with CKD and T2D and touch base on the evolution of medical guidelines over time. With a focus on GLP-1 RAs, we will be discussing how this class of medications are increasingly being recognized for their potential for the treatment of people with T2D and CKD. We will also be presenting the baseline characteristic data of the people who were the part of the FLOW clinical trial, the first dedicated kidney outcomes trial with a GLP-1 RA.

This session will last 60 minutes and will consist of a mix of short presentations, panel discussion and Q&A. During the Q&A, you will have the opportunity to ask questions and engage with the expert speakers.

I really look forward to welcoming you to this informative and interactive symposium experience.

To know more about the symposium, please visit Novo Nordisk Science Hub.

Kind Regards,

*Rubdeep Singh Bindra*

Rubdeep Singh Bindra  
Global Medical Director  
Semaglutide Diabetes, Global Medical Affairs  
Novo Nordisk

- 03 mins** **Welcome and Introduction**  
Chair: Peter Rossing (DK)

---

- 15 mins** **What are we looking for in treatment of people with CKD and T2D? (including roundtable discussion)**  
Adeera Levin (CA)

---

- 15 mins** **Clinical and treatment landscape of CKD and T2D (including roundtable discussion)**  
Roland Schmieder (DE)

---

- 15 mins** **FLOW trial population: What FLOW GLP-1 RA kidney outcomes trial will add to current knowledge? (including roundtable discussion)**  
Hiddo J.L Heerspink (NL)

---

- 10 mins** **Audience Q&A**  
All speakers

---

- 02 mins** **Closing remarks**  
Peter Rossing (DK)



Peter Rossing MD, DMSc  
Steno Diabetes Center Copenhagen,  
Denmark



Adeera Levin, MD,  
FRCPC, FCAHS, OC  
University of British Columbia,  
Canada



Roland Schmieder, MD,  
FACC, FACP, FASN, FESC  
Friedrich Alexander University  
Erlangen/Nürnberg, Germany



Hiddo J.L. Heerspink  
University Medical Center Groningen,  
Netherlands

# INDUSTRY SYMPOSIUM at ERA 2023



## Inspired to move mountains: emerging therapies in lupus nephritis

Friday 16th June, 13:30–14:30 CEST, Brown 3, MiCo, Milan

13:30–13:35	Welcome and introduction	<b>Gabriella Luisa Moroni</b>
13:35–13:50	Reaching base camp: B-cell depletion	<b>Rachel Jones</b>
13:50–14:05	One step at a time: complement inhibition	<b>Marina Vivarelli</b>
14:05–14:20	Climbing to the peak: from theory to clinical reality	<b>Liz Lightstone</b>
14:20–14:30	Q&A and close	<b>All</b>

**Roche Nephrology**

INSPIRED BY *Many*


*This symposium is not intended for physicians practicing in the US*

Veeva number: M-XX-00012844

Date of preparation: April 2023



An Industry Symposium held during the  
60th ERA Congress Milan and virtual Congress



## ANCA-associated vasculitis, the kidney and beyond

Friday 16 June 2023  
13.30-14.30 CET  
Brown 1&2

60<sup>TH</sup> ERA  
CONGRESS  
MILAN & VIRTUAL  
JUNE 15-18, 2023

### Agenda

- 13.30** Welcome and introduction  
**Chair - Dr. Andreas Kronbichler**, Addenbrooke's Hospital; University of Cambridge, Cambridge, UK
- 13.35** Targeting unmet needs in clinical practice  
**Prof. Federico Alberici**, Università degli Studi di Brescia; ASST Spedali Civili, Brescia, Italy
- 13.55** Ongoing challenges in ANCA-associated vasculitis – can we do better?  
**Dr. Silke Brix**, Manchester University NHS Foundation Trust and Division of Cell Matrix Biology and Regenerative Medicine, University of Manchester, UK
- 14.10** Q&A  
**Chair - Dr. Andreas Kronbichler**
- 14.30** Close  
**Chair - Dr. Andreas Kronbichler**

A non-promotional symposium sponsored by GSK



# ANEMIA OF CKD: TIME TO TAKE ACTION

Friday, 16 June 2023: 13:30–14:30 (CEST) | Room: Amber 1 & 2

**Act Now**

THE RED LINE OF ANEMIA OF CKD

**13:30–13:35 Welcome and introduction**

Lucia Del Vecchio

**13:35–13:55 Anemia of CKD: common, yet under-recognised?**

Ciro Esposito

**13:55–14:10 Patient-centred care to optimise current treatment**

Ciro Esposito and Frank Strutz

**14:10–14:25 Latest innovations in patient care**

Frank Strutz

**14:25–14:30 Summary and close**

Lucia Del Vecchio

*Includes insights from Angela Watt, a retired renal nurse and patient living with anemia of CKD*

*Audience Q&A will be held at the end of each presentation*



**Lucia Del Vecchio (Chair)**

Department of Nephrology and Dialysis at Sant'Anna Hospital, Como, Italy



**Ciro Esposito**

Nephrology and Dialysis Unit at ICS Maugeri, University of Pavia, Italy



**Frank Strutz**

Kidney Centre Wiesbaden-Rheumatology and DKD Helios Hospital Wiesbaden, Germany



PHARMACOSMOS LUNCH SYMPOSIUM

# Explore the latest hot topic within IV Iron in CKD and Heart Failure

Chairman: **Professor Nephrologist Loreto Gesualdo, Italy**

## TOPICS AND SPEAKERS:

*Professor Nephrologist Philip Kalra, United Kingdom*

**The value of anaemia management in a cardiorenal clinic**

*Cardiologist Fozia Ahmed, United Kingdom*

**IRONMAN Trial Design - The emerging role of IV iron to reduce cardiovascular risk, particularly the risk of hospitalisation for heart failure**

Meet the experts at this lunch symposium and gain new insights that will inspire you in your clinical practice.

This symposium will also be available virtually during and after the congress - more information will follow.

**FREE LUNCH**  
will be available at the symposium

60<sup>TH</sup> ERA  
CONGRESS  
MILAN & VIRTUAL  
JUNE 15-18, 2023

**ERA 2023, Milan**

**Date:** Friday June 16th, **Time:** 13.30 pm - 14.30 pm

**Venue:** Milano Convention Centre Viale Eginardo, 7, GATE 2, 20149 Milan, Italy Amber 3&4

PHARMACOSMOS



We cordially invite you to the Alexion, AstraZeneca Rare Disease Satellite Symposium at the 60th Annual Scientific Meeting of The European Renal Association

# What's new in the management of atypical Haemolytic Uraemic Syndrome?

Friday 16 June 2023, 13:30–14:30 (CET)

Room Amber 5, MiCo - Milano Convention Center and Virtual

Programme	Faculty
Chair's welcome and introduction Overview of management approaches to aHUS	Prof. Manuel Praga Madrid, Spain
Clinical and real-world experience with currently approved treatments for aHUS	Dr Anuja Java St. Louis, USA
Recognition and management of aHUS in the presence of associated clinical conditions or events	Dr Sjoerd Timmermans Maastricht, The Netherlands
Q&A session	All speakers
Closing remarks	All speakers

This symposium is fully funded and organised by Alexion, AstraZeneca Rare Disease. Alexion, AstraZeneca Rare Disease products may be discussed at this event. This event is intended for healthcare professionals only. Information presented at this industry-sponsored symposium is not necessarily endorsed by ERA.

The content of each presentation was prepared independently by the speaker, with limited feedback from Alexion, AstraZeneca Rare Disease. The views expressed by the speakers are not made on behalf of Alexion, AstraZeneca Rare Disease and do not necessarily represent the position of the company.

60<sup>TH</sup> ERA  
CONGRESS  
MILAN & VIRTUAL



## Hemoadsorption in Chronic and Acute Clinical Settings



Chair:  
Claudio Ronco  
Italy



Chair & Speaker  
Thomas Rimmelé  
France



Speaker:  
Vincenzo Panichi  
Italy



Speaker:  
Jinjun Chen  
China

- Improving Uremic Complications: How can Hemoadsorption Help
- Hemoadsorption in Septic Patients: Clinical Experience
- DPMAS in ACLF. The PADSTONE study on 1300 Patients

Time: 18:30-19:30 CET

Date: June 16th 2023

Room: AMBER 1&2



SYMPOSIUM

# LUPUS NEPHRITIS: current challenges and novel treatment strategies.

Friday  
June 16<sup>th</sup>, 2023  
18:30 - 19:30 CEST

Milan, Allianz MiCo,  
Amber 3 & 4

- 18:30 - 18:35 **Introduction**  
*Prof. Y. K. O. Teng*
- 18:35 - 18:55 **Current treatment:  
what are the unmet needs?**  
*Prof. L. Arnaud*
- 18:55 - 19:15 **New therapeutic options:  
is a paradigm change possible?**  
*Prof. G. L. Moroni*
- 19:15 - 19:30 **Interactive survey and live Q&A**  
*Prof. L. Arnaud,  
Prof. G. L. Moroni,  
Prof. Y. K. O. Teng*

---

**Prof. Y. K. Onno Teng - Chair**  
Leids Universitair Medisch Centrum (LUMC), NL

**Prof. Laurent Arnaud**  
Centre Hospitalier Universitaire de Strasbourg, FR

**Prof. Gabriella Luisa Moroni**  
Department of Biomedical Sciences Humanitas  
University, Milan, IT



# Novartis-sponsored satellite symposium on IgA nephropathy

## ERA 2023

### Challenges and opportunities in IgA nephropathy: Targeting the alternative complement pathway

#### Welcome from the Co-Chairs

It is our great pleasure to welcome you to the Novartis-sponsored symposium at this year's **60<sup>th</sup> European Renal Association (ERA) Congress 2023**.

The symposium entitled **Challenges and opportunities in IgA Nephropathy: Targeting the alternative complement pathway** will examine the heterogenous nature of IgAN, current management recommendations and their limitations. It will also highlight the role of the alternative complement pathway in the pathogenesis of IgAN.

Our expert faculty will explore these topics via clinical case presentations and engaging panel discussions, and we warmly encourage your active participation during the Q and A session. We hope you enjoy what will be an interesting and informative session.

**Jürgen Floege**

*(Co-Chair for IgAN symposium)*

*RWTH Aachen University, Aachen, Germany*

**Richard Lafayette**

*(Co-Chair for IgAN symposium)*

*Stanford University Medical Center, California, United States*

#### Challenges and opportunities in IgA nephropathy: Targeting the alternative complement pathway

**17 June 2023 | 10:00–11:00 (CET) | ERA Congress 2023**  
MiCo – Milano Convention Centre, Milan, Italy

Room number: Space 1 and 2, Level 0

- 10:00** **Welcome and introduction**  
Co-Chairs: Jürgen Floege and Richard Lafayette
- 10:05** **The challenges with IgAN in clinical practice today**  
Smeeta Sinha
- 10:25** **Complement in IgAN: A key driver of the pathogenesis?**  
Sydney Tang
- 10:45** **Audience Q and A**  
All faculty (moderated by the Chairs)
- 10:58** **Closing remarks**  
Co-Chairs: Jürgen Floege and Richard Lafayette

#### Faculty



**Jürgen Floege**  
**(Co-Chair)**  
RWTH Aachen University,  
Aachen, Germany



**Richard Lafayette**  
**(Co-Chair)**  
Stanford University Medical Center,  
California, United States



**Smeeta Sinha**  
Salford Royal NHS Foundation  
Trust, Salford, United Kingdom  
University of Manchester,  
Manchester, United Kingdom



**Sydney Tang**  
The University of  
Hong Kong, Pokfulam,  
Hong Kong

ERA 2023  
hybrid



Industry Session on the occasion of ERA Congress 2023  
**Strengthening expertise in the treatment of chronic kidney disease**

ERA Congress 2023, Milan and virtual

21

**Saturday, 17 June 2023 | 10:00 – 11:00 CEST** Milano Convention Centre, Space 3&4 and virtual

**Chair:** Malyszko, Jolanta (Warsaw, Poland)

**10:00 – 10:05 Welcome & Introduction**  
Malyszko, Jolanta (Warsaw, Poland)

**10:05 – 10:20 Challenges and opportunities in the treatment in CKD**  
Wheeler, David (London, UK)

**10:20 – 10:35 Improving clinical outcomes in CKD: novel approaches**  
Pontremoli, Roberto (Genoa, Italy)

**10:35 – 10:50 Commentary: Practical considerations for CKD management**

Borg, Rikke (Roskilde, Denmark)

**10:50 – 11:00 Discussion & Closure**

Malyszko, Jolanta (Warsaw, Poland)

▶ [Program of the industry session](#)



Supported by a Medical Education Grant from Boehringer Ingelheim and Lilly Alliance  



SCIENCE COLLECTED

# Continuing lifesaving therapy in the cardiorenal patient: Practical guidance for managing hyperkalemia

Saturday, 17<sup>th</sup> June 2023, 10:00 – 11:00 CEST  
MiCo South - Level +2



**James Burton (Chair)**  
University of Leicester  
UK



**Manish Sood**  
University of Ottawa  
Canada



**Shelley Zieroth**  
University of Manitoba  
Canada

## Agenda

Time	Session	Speaker
10:00 – 10:05	Welcome and introductions	James Burton
10:05 – 10:15	Catch-22 – hyperkalemia and RAASi	Manish Sood
10:15 – 10:45	Reaching consensus – Optimising care for cardiorenal patients <i>Panel Discussion</i>	All faculty
10:45 – 10:55	Panel discussion and Q&A	All faculty
10:55 – 11:00	Closing remarks	James Burton



This symposium is accredited for 1 CME credit  
by Royal College of Physicians



Supported by an unrestricted educational grant from AstraZeneca.



ERA hybrid congress 2023  
Milan, Italy & virtual  
15–18 June 2023



# Through different lenses: understanding the complexity of C3G and IC-MPGN

Saturday, 17 June 2023  
10:00–11:00 CEST



A multidisciplinary expert panel featuring...

**Chair's welcome**

Fernando Caravaca-Fontán, Spain

**Beneath the surface: the heterogeneous pathophysiology of C3G/IC-MPGN**

Marina Noris, Italy

**Demystifying the diagnostic pathway and disease progression in C3G/IC-MPGN**

Fernando Caravaca-Fontán, Spain


**The patient voice: the uncertainty of living with severe progressive kidney disease**

Antonia King, Germany

**Closing remarks and Q&A:  
Can we redefine the future of patient management in C3G/IC-MPGN?**

All faculty

Chair: Fernando Caravaca-Fontán, Spain





60<sup>th</sup> ERA CONGRESS MILAN & VIRTUAL

# Filling the Gap by Targeting the Gut

First Disease Modifying Treatment Approved for IgAN

Saturday June 17<sup>th</sup>, 10:00–11:00 CET  
Room Amber 1 & 2 (Level +2) & Virtual



Chair

**Prof. Paolo Schena**

Professor Emeritus at the University of Bari, Italy. Shaping IgA nephropathy since 40 years with more than 100 relevant publications in the field.



Speaker

**Prof. Bengt Fellström**

Senior Professor at the Uppsala University Hospital in Sweden. Lead author of the Phase 2 Nefigan trial.



Speaker

**Prof. Jonathan Barratt**

Mayer Professor of Renal Medicine at the University of Leicester, UK. Lead author of the Phase 3 Nefigard trial.

## Filling the Gap by Targeting the Gut

First Disease Modifying Treatment Approved for IgAN

### PROGRAM

10:00–10:10

Welcome and Introduction  
Prof. Paolo Schena

10:10–10:30

Nefecon – Rationale, Efficacy and Safety in the Treatment of Primary IgA Nephropathy  
Prof. Bengt Fellström

10:30–10:50

Nefigard and Beyond – Treating IgA Nephropathy in 2023  
Prof. Jonathan Barratt

10:50–11:00

Discussion and Closing Remarks

IgAN: Immunoglobulin A Nephropathy



Live and on-demand

Come visit our booth  
**D.110**

STADA Arzneimittel AG  
Stadastraße 2–18  
61118 Bad Vilbel  
Germany





AsahiKASEI

# Therapeutic Apheresis: FUTURE CHALLENGES



June 17<sup>th</sup> - 10:00-11:00

Room Amber 3&4

---

**Chairman Dr. Emanuela de Pascale** Napoli, Italy

**Co-Chairman Prof. Reinhard Klingel** Cologne, Germany

---



10:00

**Dr. Benjamin Savenkoff**

Metz-Thionville, France

**An apheresis centre – novel interdisciplinary treatment opportunities for nephrologists.**



10:15

**Prof. Reinhard Klingel**

Cologne, Germany

**Lipoprotein apheresis – Quo vadis?**



10:30

**Prof. Bernd Hohenstein**

Villingen-Schwenningen, Germany

**Post-COVID-19 syndrome – is there a role for apheresis?**

# PATIENT-CENTRED CARE IN DIALYSIS: LET'S TACKLE CKD-ASSOCIATED PRURITUS

Saturday 17 June 2023, 10.00–11.00 CEST  
Room Amber 5, MiCo – Milano Convention Centre, Italy

Dear Colleague,

It is my pleasure to invite you to this CSL Vifor-sponsored educational symposium, entitled '**Patient-centred care in dialysis: let's tackle CKD-associated Pruritus**', as part of the 60th ERA congress in Milan.

CKD-associated Pruritus is a condition that significantly impacts the quality of life and medical outcomes of patients receiving haemodialysis. Despite this, CKD-associated Pruritus is under-reported, under-recognised and options for its treatment have previously been suboptimal. However, the increasing recognition of symptom-oriented care and the changing treatment landscape for CKD-associated Pruritus provides new opportunities for nephrologists to support patients in their quest for an improved quality of life.

The expert faculty will provide an overview of CKD-associated Pruritus and share their experience of its management. The symposium will conclude with a live Q&A session, providing an opportunity for audience questions be addressed.

We look forward to welcoming you to this exciting, educational symposium.



Professor Lucio Manenti  
Chair

60<sup>TH</sup> ERA  
CONGRESS  
MILAN & VIRTUAL  
JUNE 15-18, 2023

## PROGRAMME

### Welcome and introduction

Lucio Manenti, Italy (Chair)

### An insight into the burden and prevalence of CKD-associated Pruritus

Antoine Lanot, France

### An opportunity to improve CKD-associated Pruritus: sharing clinical experience of difelikefalin

Leonie Kraft, Germany and  
Joerg Latus, Germany

### A changing landscape for the treatment of CKD-associated Pruritus

Lucio Manenti, Italy (Chair)

### Audience Q&A

All

### Summary and meeting close

Lucio Manenti, Italy (Chair)





# Achieving Success in IgAN & FSGS: Expert Insights on Current and Future Therapies

Saturday, June 17, 2023 | 13:30 – 14:30 CEST  
Milan Convention Center, Level 0 – Space 1 & 2

**CME-ACCREDITED SYMPOSIUM TO BE HELD DURING ERA 2023**

Learn about novel mechanisms and emerging data in IgAN and FSGS.

After attending this symposium, attendees will be able to:

- Improve their diagnosis of immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)
- Discuss current treatment considerations of IgAN and FSGS
- Develop treatment plans to lower proteinuria in patients with IgAN and FSGS
- Review emerging treatment approaches for IgAN and FSGS
- Interpret emerging clinical trial data in IgAN and FSGS

## CHAIR:

**Siân Griffin, MD, PhD**  
Consultant Nephrologist  
Honorary Professor, Cardiff University  
Department of Nephrology and Transplantation  
University Hospital of Wales  
Cardiff, United Kingdom

## FACULTY:

**Jürgen Floege, MD**  
Director, RWTH Aachen University Hospital  
Aachen, Germany

**Loreto Gesualdo, MD, FERA**  
Full Professor of Nephrology  
University of Bari Aldo Moro  
Bari, Italy

The ERA assumes no responsibility for the information published in this document.

This activity is supported by an independent educational grant from CSL Vifor. The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting *AMA PRA Category 1 Credits™* to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at [mutualrecognition@uems.eu](mailto:mutualrecognition@uems.eu).

SCIENCE COLLECTED

# RESHAPING KIDNEY CARE



**Kieran McCafferty (Chair)**  
Barts Health NHS Trust  
London, UK



**David Cherney**  
University of Toronto,  
Canada



**Paola Fioretto**  
University of Padova  
Italy

## AGENDA

Duration	Session	Speaker
13:30 – 13:35	Welcome and introductions	Kieran McCafferty
13:35 – 13:45	From early to late in CKD – nephrologists and their role before secondary care	Kieran McCafferty
13:45 – 14:00	Time to make fozination a standard-of-care	David Cherney
14:00 – 14:15	Overcoming barriers to the use of SGLT2 inhibitors – I Learnings from our journey so far	Paola Fioretto
14:15 – 14:25	Panel discussion and Q&A	All faculty
14:25 – 14:30	Closing remarks	Kieran McCafferty

ESTABLISHING THE FULL POTENTIAL OF  
SGLT2 INHIBITORS AS STANDARD-OF-CARE

**SATURDAY, 17<sup>TH</sup> JUNE 2023 | 13:30–14:30**

**MICO SOUTH | LEVEL 0 | ROOM SPACE 3&4**



This symposium is accredited for 1 CME credit by Royal College of Physicians




Supported by an unrestricted educational grant from AstraZeneca.



# ERA 2023

60<sup>th</sup> European Renal Association Congress  
15-18 June | Allianz MiCo, Milan, ITALY



LUNCH SYMPOSIUM 17 June | 13:30-14:30 | BROWN Hall 3


## Immuno-nephrology: the dialysis membrane as a therapeutic strategy

*G. Castellano (Milan, Italy) and I. Masakane (Yamagata, Japan)*

- 13:30-13:48**      **Transplant-waitlisted patients and DGF: role of PMMA membrane**  
*G. Castellano (Milan, Italy)*
- 13:48-14:06**      **New frontier of anti-thrombogenic membrane: technology and clinical applications**  
*P. Rieu (Reims, France)*
- 14:06-14:24**      **Inhibiting complement activation in septic AKI: why consider PMMA-based dialysis**  
*V. Cantaluppi (Novara, Italy)*
- 14:24-14:30**      **Discussion**

Supported by: Toray Medical Co.,Ltd.





60<sup>th</sup> ERA Congress, Milan and virtual

## Hemocompatibility of dialyzers – How novel membranes may improve hemodialysis treatment

Industry Symposium

Saturday, June 17<sup>th</sup> 13:30 – 14:30

Room: Brown 1 & 2 and live stream

**Chair:**

Prof. Dr. Alberto Ortiz, University of Madrid, Spain

**Clinical expectations on  
hemocompatibility of dialyzers**

Prof. Dr. Alberto Ortiz, Spain

**Biocompatibility of dialyzer membranes:  
relevance in current clinical practice**

Assoc. Prof. Dr. Muriel Grooteman,  
the Netherlands

**Inflammation – the fire that burns within**

Prof. Dr. Peter Stenvinkel, Sweden

**From bench to bedside – the develop-  
ment of a novel hydrolayer membrane**

Ass. Prof. Dr. Fatih Kircelli, GMO  
Fresenius Medical Care, Germany



Industry session on the occasion of the European Renal Association congress 2023

As an expert in this area of clinical practice, we are delighted to invite you to participate in the Bayer symposium titled

## Non-steroidal MRAs: A new pillar of treatment for cardiorenal protection in CKD and T2D

Saturday 17 June; 13:30–14:30

Chair: Guiseppe Grandaliano

Beatriz Fernandez Fernandez

Christoph Wanner

Rajiv Agarwal

The symposium offers a unique opportunity to gain an overview of the most recent guideline updates related to CKD and T2D and the need for a comprehensive and holistic approach to the patient management. To discuss the use of the 'pillar approach' to manage CKD in T2D and how to use finerenone in clinical practice based on expert experience. To highlight the relevance of the urgency to treat CKD in T2D to improve cardiorenal outcomes.

31

13:30 – 13:35	<b>Welcome and introductions</b>	Guiseppe Grandaliano
13:35 – 13:45	<b>Nonsteroidal MRAs as part of the comprehensive approach to CKD: Guidelines update</b>	Beatriz Fernandez Fernandez
13:45 – 14:00	<b>Pillar approach for the treatment of CKD in T2D: treat early to help prevent further CV and renal damage</b>	Christoph Wanner
14:00 – 14:15	<b>Beyond CKD progression: cardiorenal protection across the spectrum of CKD in patients with T2D</b>	Rajiv Agarwal
14:15 – 14:30	<b>Q&amp;A and closing</b>	All

Official ERA'23 sponsored symposium

MA-M\_FIN-ALL-1178-1

Astellas-sponsored symposium

**Complex pathophysiology and management in anaemia of CKD: is roxadustat the answer?**  
**Simplicity through innovation**

Saturday 17 June 2023 | 13:30–14:30 CEST | Amber 3 & 4, Level +2, MiCo

Faculty:



**Chairperson:**  
**Professor**  
**Mario Cozzolino**  
University of Milan,  
Italy



**Professor**  
**Denis Fouque**  
University Claude  
Bernard, Lyon, France



**Professor**  
**Roberto Minutolo**  
University of Campania,  
Naples, Italy



**Dr Monica Gross**  
DaVita Falkensee,  
Germany

Time	Session	Speaker
13:30–13:35	Welcome and introductions	Professor Mario Cozzolino
13:35–13:45	The complexities of anaemia of CKD: disease burden, pathophysiology and management	Professor Denis Fouque
13:45–14:10	Roxadustat and the impact of a physiological approach to treatment	Professor Roberto Minutolo
14:10–14:25	Roxadustat in the real-world: the patient experience	Dr Monica Gross
14:25–14:30	Q&A and meeting close	All

“The symptoms of anaemia can be debilitating for our patients and effective management is key to improving quality of life and reducing the risk of adverse outcomes of anaemia in this challenging population.

This symposium will draw on the experience of the faculty to explore the clinical evidence, real-world experience, practicalities and potential of roxadustat, the first HIF-prolyl hydroxylase inhibitor to be approved for the treatment of adult patients with anaemia of CKD.

Professor Mario Cozzolino

CKD, chronic kidney disease; HIF, hypoxia-inducible factor.

This symposium is sponsored by Astellas and is intended for healthcare professionals only. This symposium contains information about Astellas products.

MAT-IT-EVZ-2023-00032 | Date of prep: April 2023 | Expiry date: July 2023. © 2023 Astellas Pharma Inc. or its affiliates. All trademarks are the property of their respective owners.







# Ensuring a **treatment continuum** for CKD-MBD

Saturday 17 June 2023, 13.30–14.30 CEST

Room Amber 5  
MiCo – Milano Convention Centre, Italy

Dear Colleague,

It is my pleasure to invite you to this CSL Vifor-sponsored educational symposium, entitled '**Ensuring a treatment continuum for CKD-MBD**', as part of the 60<sup>th</sup> ERA congress in Milan.

The chronic kidney disease-mineral bone disorder (CKD-MBD) continuum describes a spectrum of conditions resulting from progressive deterioration of hormonal and mineral homeostasis, and subsequent alterations in laboratory parameters, including serum phosphate, calcium, parathyroid hormone and vitamin D. CKD-MBD can affect patients across all stages of CKD, and may lead to severe clinical outcomes, including vascular calcification and increased mortality.

During this informative symposium, the expert faculty will introduce a holistic approach to managing CKD-MBD, emphasising the need for effective treatment and quality patient care from the early, non-dialysis stages of CKD to stage 5 CKD. Specifically, the discussions will focus on the management of secondary hyperparathyroidism (SHPT) and hyperphosphataemia.

The symposium will conclude with a live Q&A session, during which we will address questions from the audience.

This year, we are pleased to welcome both an in-person and virtual audience to our exciting symposium, bringing together colleagues from across the globe to discuss the importance of effective management across the CKD-MBD continuum.

**Smeeta Sinha**  
Chair

The ERA assumes no responsibility for the information published in this document.

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the congress organiser to hold the symposium.

Approval conditions for drugs mentioned during the symposium may vary from country to country. Before prescribing, always refer to the local SmPCs. Materials related to this product are intended for healthcare professionals from Europe.

## Programme

- 13.30 Welcome and introduction to vascular calcification**  
Smeeta Sinha, UK (Chair)
- 13.45 Importance of early and effective treatment of SHPT in non-dialysis CKD patients**  
Jan Kielstein, Germany
- 14.05 Decreasing pill burden in dialysis patients: advances in hyperphosphataemia treatment**  
Maria Jesús Lloret, Spain
- 14.25 Key takeaways from the panel and close**  
All/Smeeta Sinha, UK (Chair)



Click [HERE](#) or scan the QR code to register for ERA 2023 and to gain access to this session.

Lunch will be provided

